Sanofi (EPA:SAN) PT Set at €85.00 by Barclays

Sanofi (EPA:SAN) received a €85.00 ($98.84) price objective from equities researchers at Barclays in a note issued to investors on Wednesday, Borsen Zeitung reports. The firm presently has a “sell” rating on the stock. Barclays‘s price target points to a potential downside of 7.99% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Goldman Sachs Group set a €100.00 ($116.28) price objective on Sanofi and gave the company a “neutral” rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. set a €103.00 ($119.77) target price on Sanofi and gave the stock a “buy” rating in a report on Wednesday. Credit Suisse Group set a €105.00 ($122.09) target price on Sanofi and gave the company a “buy” rating in a research report on Friday, February 7th. Kepler Capital Markets set a €99.00 ($115.12) price target on Sanofi and gave the company a “buy” rating in a report on Monday. Finally, HSBC set a €84.00 ($97.67) price target on Sanofi and gave the company a “neutral” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Sanofi has an average rating of “Buy” and an average price target of €98.35 ($114.36).

SAN opened at €92.38 ($107.42) on Wednesday. The stock has a 50-day moving average of €90.70 and a 200 day moving average of €83.59. Sanofi has a 12 month low of €63.09 ($73.36) and a 12 month high of €92.97 ($108.10).

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Further Reading: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.